63. Idiopathic thrombocytopenic purpura
311 clinical trials,   185 drugs   (DrugBank: 39 drugs),   43 drug target genes,   132 drug target pathways
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00244257 (ClinicalTrials.gov) | August 2005 | 25/10/2005 | Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) | Phase I, Open-Label, Multi-center, Single-Dose, Dose-Escalating, Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura | Biological: GMA161 | Genzyme, a Sanofi Company | NULL | Terminated | 18 Years | N/A | Both | 10 | Phase 1 | United States |